Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 1/2010

01-03-2010

Galectin-3 in Cardiac Remodeling and Heart Failure

Authors: Rudolf A. de Boer, Lili Yu, Dirk J. van Veldhuisen

Published in: Current Heart Failure Reports | Issue 1/2010

Login to get access

Abstract

Galectin-3 is a member of the galectin family, which consists of animal lectins that bind β-galactosides. Recently, a role for galectin-3 in the pathophysiology of heart failure has been suggested. It was observed that galectin-3 is specifically upregulated in decompensated heart failure compared with compensated heart failure in animal models of heart failure. This has been associated with activation of fibroblasts and macrophages, which are a hallmark of cardiac remodeling. Therefore, galectin-3 may be a culprit biomarker in heart failure. Initial clinical observations indicate that galectin-3 may be a useful biomarker for decompensated heart failure, with incremental value over well-used “pressure-dependent” biomarkers, such as B-type natriuretic peptide. Future studies should focus on galectin-3 biology to better address the usefulness of galectin-3 as a biomarker and probe the usefulness of anti-galectin-3 therapy in treating heart failure.
Literature
1.
Barondes SH, Cooper DNW, Gitt MA, Leffler H: Galectins: structure and function of a large family of animal lectins. J Biol Chem 1994, 269:20807–20810.PubMed
2.
3.
Wang JL, Laing JG, Anderson RL: Lectins in the cell nucleus. Glycobiology 1991, 3:243–252.CrossRef
4.
•• Yang RY, Rabinovich GA, Liu FT: Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008, 13:e17–e39. This excellent review article provides insight regarding galectin biology.CrossRef
5.
Elola MT, Wolfenstein-Todel C, Troncoso MF, et al.: Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007, 64:1679–1700.PubMedCrossRef
6.
Liu FT, Patterson RJ, Wang JL: Intracellular functions of galectins. Biochim Biophys Acta 2002, 1572:263–273.PubMedCrossRef
7.
Wang JL, Laing JG, Anderson RL: Lectins in the cell nucleus. Glycobiology 1991, 3:243–252.CrossRef
8.
Hughes RC: Mac-2: a versatile galactose-binding protein of mammalian tissues. Glycobiology 1994, 4:5–12.PubMedCrossRef
9.
Birdsall B, Feeney J, Burdett IDJ, et al.: NMR solution studies of hamster galectin-3 and electron microscopic visualization of surface-adsorbed complexes: evidence for interactions between the N-and C-terminal domains. Biochemistry 2001, 40:4859–4866.PubMedCrossRef
10.
Krześlak A, Lipińska A: Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004, 9:305–328.PubMed
11.
Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S: Mac-2-binding glycoproteins. Putative ligands for a cytosolic β-galactoside lectin. J Biol Chem 1991, 266:18731–18736.
12.
Sato S, Hughes RC: Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem 1992, 267:6983–6990.PubMed
13.
Ochieng J, Furtak V, Lukyanov P: Extracellular functions of galectin-3. Glycoconj J 2004, 19:527–535.PubMedCrossRef
14.
Nakahara S, Oka N, Wang Y, et al.: Characterization of the nuclear import pathways of galectin-3. Cancer Res 2006, 66:9995–10006.PubMedCrossRef
15.
Menon RP, Hughes RC: Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem 1999, 264:569–576.PubMedCrossRef
16.
Mehul B, Hughes RC: Plasma membrane targeting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. J Cell Sci 1997, 110:1169–1178.PubMed
17.
Hughes RC: The galectin family of mammalian carbohydrate-binding molecules. Biochem Soc Transact 1997, 25:1194–1198.
18.
Hughes RC: Secretion of the galectin family of mammalian carbohydrate-binding family proteins. Biochem Biophys Acta 1999, 1473:172–185.PubMedCrossRef
19.
Kim H, Lee J, Hyun JW, et al.: Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007, 31:655–662.PubMedCrossRef
20.
Sharma UC, Pokharel S, van Brakel TJ, et al.: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121–3128.PubMedCrossRef
21.
Lee MA, Böhm M, Paul M, et al.: Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 1996, 270:E919–E929.PubMed
22.
de Boer RA, Pokharel S, Flesch M, et al.: Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004, 82:678–687.PubMedCrossRef
23.
Schroen B, Heymans S, Sharma U, et al.: Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004, 95:515–522.PubMedCrossRef
24.
Thandavarayan RA, Watanabe K, Ma M, et al.: 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol 2008, 75:1797–1806.PubMedCrossRef
25.
Sharma U, Rhaleb NE, Pokharel S, et al.: Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol 2008, 294:H1226–H1232.
26.
• Liu YH, D’Ambrosio M, Liao TD, et al.: N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009, 296:H404–H412. This article evaluates anti-galectin-3 therapy and demonstrates how it may reverse adverse cardiac remodeling, providing support for the hypothesis that anti-galectin therapy may be feasible.PubMedCrossRef
27.
Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247–2250.PubMedCrossRef
28.
Brown RD, Ambler SK, Mitchell MD, Long CS: The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005, 45:657–687.PubMedCrossRef
29.
de Cavanagh EM, Ferder M, Inserra F, Ferder L: Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol 2009, 296:H550–H558.PubMedCrossRef
30.
Hsu DK, Dowling CA, Jeng KC, et al.: Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999, 81:519–526.PubMedCrossRef
31.
Henderson NC, Mackinnon AC, Farnworth SL, et al.: Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006, 103:5060–5065.PubMedCrossRef
32.
Nishi Y, Sano H, Kawashima T, et al.: Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007, 56:57–65.PubMedCrossRef
33.
Wang L, Friess H, Zhu Z, et al.: Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest 2000, 80:1223–1241.CrossRef
34.
Sasaki S, Bao Q, Hughes RC: Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 1999, 187:481–489.PubMedCrossRef
35.
• Henderson NC, Mackinnon AC, Farnworth SL, et al.: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008, 172:288–298. This experimental study underscores the pivotal role of galectin-3 in the fibrosis process. Employing galectin-3 deficient mice, the authors show that galectin-3 regulates renal fibrosis.PubMedCrossRef
36.
Eis V, Luckow B, Vielhauer V, et al.: Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol 2004, 15:337–347.PubMedCrossRef
37.
Vlassara H, Li YM, Imani F, et al.: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995, 1:634–646.PubMed
38.
Hartog JW, Voors AA, Bakker SJ, et al.: Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007, 9:1146–1155.PubMedCrossRef
39.
Iacobini C, Oddi G, Menini S, et al.: Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice. Am J Physiol 2005, 289:F611–F621.CrossRef
40.
Iacobini C, Menini S, Oddi G, et al.: Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004, 18:1773–1775.PubMed
41.
42.
Reifenberg K, Lehr HA, Torzewski M, et al.: Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol 2007, 171:463–472.PubMedCrossRef
43.
van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al.: Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48:1217–1224.PubMedCrossRef
44.
Milting H, Ellinghaus P, Seewald M, et al.: Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008, 27:589–596.PubMedCrossRef
45.
Lin YH, Lin LY, Wu YW, et al.: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96–99.PubMedCrossRef
46.
• de Boer RA, Voors AA, Muntendam P, et al.: Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11:811–817. This article provides a complete overview of the potential role of galectin-3 in the pathophysiology of heart failure.PubMedCrossRef
47.
Dickstein K, Cohen-Solal A, Filippatos G, et al.: ESC guidelines for the diagnosis treatment of acute, chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933–989.PubMedCrossRef
Metadata
Title
Galectin-3 in Cardiac Remodeling and Heart Failure
Authors
Rudolf A. de Boer
Lili Yu
Dirk J. van Veldhuisen
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Current Heart Failure Reports / Issue 1/2010
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-010-0004-x

Other articles of this Issue 1/2010

Current Heart Failure Reports 1/2010 Go to the issue

OriginalPaper

Exercise in the Management of Patients with Chronic Heart Failure

OriginalPaper

Percutaneous Mitral Valve Repair: Potential in Heart Failure Management

OriginalPaper

Neuregulin Signaling and Heart Failure

OriginalPaper

Understanding the C-Pulse Device and Its Potential to Treat Heart Failure

OriginalPaper

ST2: A Novel Remodeling Biomarker in Acute and Chronic Heart Failure

OriginalPaper

An Update on Cardiac Troponins as Circulating Biomarkers in Heart Failure
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits